Almost all prostate cancer patients become resistant to therapy that blocks androgen-mediated cell proliferation. The key to this resistance may lie in expression of the androgen receptor itself (pages 33–39).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
In-silico activity prediction and docking studies of some flavonol derivatives as anti-prostate cancer agents based on Monte Carlo optimization
BMC Chemistry Open Access 26 July 2023
-
The prohibitin-repressive interaction with E2F1 is rapidly inhibited by androgen signalling in prostate cancer cells
Oncogenesis Open Access 15 May 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Chen, C.D. et al. Nat. Med. 10, 33–39 (2004).
Litvinov, I.V., De Marzo, A.M. & Isaacs, J.T. J. Clin. Endocrinol. Metab. 88, 2972–2982 (2003).
Gao, J., Arnold, J.T. & Isaacs, J.T. Cancer Res. 61, 5038–5044 (2001).
Kyprianou, N., English, H.F. & Isaacs, J.T. Cancer Res. 50, 3748–3753 (1990).
Hobisch, A. et al. Urol. Int. 65, 73–79 (2000).
Linja, M.J. et al. Cancer Res. 61, 3550–3555 (2001).
Edwards, J., Krishna, N.S., Grigor, K.M. & Bartlett, J.M.S. Br. J. Cancer 89, 552–556 (2003).
Scher, H.I. & Kelly, W.K. J. Clin. Oncol. 11, 1566–1572 (1993).
Schellhammer, P.F. et al. J. Urol. 157, 1731–1735 (1997).
Comuzzi, B. et al. Am. J. Pathol. 162, 233–241 (2003).
Bakin, R.E., Gioeli, D., Sikes, R.A., Bissonette, E.A. & Weber, M.J. Cancer Res. 63, 1981–1989 (2003).
Rahman, M.M. et al. J. Biol. Chem. 278, 19619–19626 (2003).
Adam, R.M. et al. Endocrinol. 143, 4599–4608 (2002).
Solit, D.B. et al. Clin. Cancer Res. 8, 962–966 (2002).
Eder, I.E. et al. Cancer Gene Ther. 9, 117–125 (2002).
Zegarra-Moro, O.L., Schmidt, L.J., Huang, H. & Tindall, D.J. Cancer Res. 62, 1008–1013 (2002).
Mitchell, S.H., Zhu, W. & Young, C.Y. Cancer Res. 59, 5892–5895 (1999).
Rimler, A. et al. Prostate 49, 145–154 (2001).
Zhu, W., Zhang, J.S. & Young, C.Y. Carcinogenesis 22, 1399–1403 (2001).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Isaacs, J., Isaacs, W. Androgen receptor outwits prostate cancer drugs. Nat Med 10, 26–27 (2004). https://doi.org/10.1038/nm0104-26
Issue Date:
DOI: https://doi.org/10.1038/nm0104-26
This article is cited by
-
In-silico activity prediction and docking studies of some flavonol derivatives as anti-prostate cancer agents based on Monte Carlo optimization
BMC Chemistry (2023)
-
The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications
Nature Reviews Urology (2023)
-
The microRNA signatures: aberrantly expressed miRNAs in prostate cancer
Clinical and Translational Oncology (2019)
-
A Targeted Bivalent Androgen Receptor Binding Compound for Prostate Cancer Therapy
Hormones and Cancer (2019)
-
The prohibitin-repressive interaction with E2F1 is rapidly inhibited by androgen signalling in prostate cancer cells
Oncogenesis (2017)